March 3, 2026Open Access

FPSIR predicts clinical therapeutic responses and survival outcomes in patients with metastatic colorectal cancer undergoing first-line bevacizumab-containing chemotherapy

Puntos clave

FPSIR was identified as a strong biomarker predicting clinical efficacy and prognosis.
Patients with metastatic colorectal cancer undergoing bevacizumab-containing chemotherapy showed promising outcomes based on FPSIR levels.
Analysis assessed clinical efficiency using FPSIR as a predictive tool within a cohort of mCRC patients.
The findings highlight a significant step toward personalized treatment in advanced colorectal cancer.

Resumen

Pretreatment FPSIR was identified as a robust biomarker for predicting clinical efficacy and prognosis in mCRC patients receiving first-line Bev/CT, providing a promising strategy to address the long-standing challenge of treatment stratification.

Me gusta

Guardar

Ver artículo completo